EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial

Bart L Clarke, Aliya A Khan, Mishaela R Rubin, Peter Schwarz, Tamara Vokes, Dolores M Shoback iD, Claudia Gagnon iD, Andrea Palermo iD, Lisa G Abbott, Lorenz C Hofbauer, Lynn Kohlmeier, Filomena Cetani iD und 8 weitere

The Journal of Clinical Endocrinology & Metabolism · 17.03.2025 · 110 (4) · 951-960

DOI: 10.1210/clinem/dgae693 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 08.10.2024. Verfasst von Bart L Clarke und 19 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology, Mayo Clinic E18-A, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Hypoparathyroidism, Parathyroid Hormone. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ascendis Pharma Bone Diseases A/S, Hellerup, Denmark.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Conventional therapy for hypoparathyroidism aims to alleviate symptoms of hypocalcemia but does not address insufficient parathyroid hormone (PTH) levels.

Objective

Assess the long-term efficacy and safety of TransCon PTH (palopegteriparatide) for hypoparathyroidism.

Design

Phase 3 trial with a 26-week, double-blind, placebo-controlled period followed by a 156-week, open-label extension (OLE).

Setting

Twenty-one sites across North America and Europe.

Participants

A total of 82 adults with hypoparathyroidism were randomized and received study drug and 78 completed week 52. Intervention(s) All OLE participants received TransCon PTH administered once daily. Main Outcome Measure(s) Multicomponent efficacy endpoint: proportion of participants at week 52 who achieved normal serum calcium (8.3-10.6 mg/dL) and independence from conventional therapy (≤600 mg/day of elemental calcium and no active vitamin D). Other efficacy endpoints included patient-reported outcomes and bone mineral density. Safety was assessed by 24-hour urine calcium and treatment-emergent adverse events.

Results

At week 52, 81% (63/78) met the multicomponent efficacy endpoint, 95% (74/78) achieved independence from conventional therapy, and none required active vitamin D. Patient-reported outcomes showed sustained improvements in quality of life, physical functioning, and well-being. Mean bone mineral density Z-scores decreased toward age- and sex-matched norms from baseline to week 52. Mean (SD) 24-hour urine calcium excretion decreased from 376 (168) mg/day at baseline to 195 (114) mg/day at week 52. Most treatment-emergent adverse events were mild or moderate and none led to trial discontinuation during the OLE.

Conclusion

At week 52 of the PaTHway trial, TransCon PTH showed sustained efficacy, safety, and tolerability in adults with hypoparathyroidism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypoparathyroidismParathyroid HormoneHumansFemaleMaleMiddle AgedAdultDouble-Blind MethodCalciumBone DensityTreatment OutcomeAgedQuality of Life

Stichwörter der Autor:innen

hormone replacement therapyhypocalcemiahypoparathyroidismpalopegteriparatideparathyroid hormonequality of life

Substanzen

Parathyroid HormoneCalcium

Autor:innen und Institutionen

  • Endocrinology, Mayo Clinic E18-A, Rochester, MN 55905, USA.
  • Endocrinology, Metabolism, and Geriatrics, McMaster University, Hamilton, ON L8S 4L8, Canada.
  • Endocrinology, Columbia University, New York, NY 10032, USA.
  • Internal Medicine and Endocrinology, Rigshospitalet, 2100 Copenhagen, Denmark.
  • Endocrinology, Diabetes, and Metabolism, University of Chicago, Chicago, IL 60637, USA.
  • Endocrinology, VA Medical Center, University of California, San Francisco, San Francisco, CA 94143, USA.

ORCID-Profile: Dolores M Shoback, Claudia Gagnon, Andrea Palermo, Filomena Cetani, Aimee D Shu, Lars Rejnmark

Förderung

  • Ascendis Pharma Bone Diseases A/S, Hellerup, Denmark

Zitieren

APA

Clarke, B. L., Khan, A. A., Rubin, M. R., Schwarz, P., Vokes, T., Shoback, D. M., Gagnon, C., Palermo, A., Abbott, L. G., Hofbauer, L. C., Kohlmeier, L., Cetani, F., Pihl, S., An, X., Smith, A. R., Lai, B., Ukena, J., Sibley, C. T., Shu, A. D., & Rejnmark, L. (2025). Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. The Journal of Clinical Endocrinology & Metabolism, 110(4), 951-960. https://doi.org/10.1210/clinem/dgae693

Vancouver

Clarke BL, Khan AA, Rubin MR, Schwarz P, Vokes T, Shoback DM, et al. Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. The Journal of Clinical Endocrinology & Metabolism. 2025;110(4):951-960. doi:10.1210/clinem/dgae693

BibTeX
@article{Clarke2025,
  author = {Clarke, Bart L and Khan, Aliya A and Rubin, Mishaela R and Schwarz, Peter and Vokes, Tamara and Shoback, Dolores M and Gagnon, Claudia and Palermo, Andrea and Abbott, Lisa G and Hofbauer, Lorenz C and Kohlmeier, Lynn and Cetani, Filomena and Pihl, Susanne and An, Xuebei and Smith, Alden R and Lai, Bryant and Ukena, Jenny and Sibley, Christopher T and Shu, Aimee D and Rejnmark, Lars},
  title = {Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {4},
  pages = {951--960},
  doi = {10.1210/clinem/dgae693}
}
Kostenlos starten →